Letters
No evidence of increased risk of acquired rifampin resistance
Dick Menzies, Victoria Cook, Richard Long and Rovina Ruslami
CMAJ November 25, 2019 191 (47) E1314-E1315; DOI: https://doi.org/10.1503/cmaj.73353
Dick Menzies
Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Que.
MD MScVictoria Cook
Clinical associate professor, Department of Medicine, University of British Columbia, Vancouver, BC
MDRichard Long
Professor, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta.
MDRovina Ruslami
Professor, Department of Biomedical Sciences, Division of Pharmacology & Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
MD PhDData supplements
Uncorrected version
Related Articles
- Batt, J., & Khan, K. (2019). Responsible use of rifampin for the treatment of latent tuberculosis infection. CMAJ, 191(25), E678-E679. Accessed August 17, 2024. https://doi.org/10.1503/cmaj.190081.
- (2020). No evidence of increased risk of acquired rifampin resistance. CMAJ, 192(9), E222. Accessed August 17, 2024. https://doi.org/10.1503/cmaj.200235.
In this issue
Article tools
Respond to this article
No evidence of increased risk of acquired rifampin resistance
Dick Menzies, Victoria Cook, Richard Long, Rovina Ruslami
CMAJ Nov 2019, 191 (47) E1314-E1315; DOI: 10.1503/cmaj.73353